Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, rest of Latin America, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is headquartered in Karmiel, Israel.
IPO Year:
Exchange: AMEX
Website: protalix.com
| Date | Price Target | Rating | Analyst |
|---|
10-Q - Protalix BioTherapeutics, Inc. (0001006281) (Filer)
8-K - Protalix BioTherapeutics, Inc. (0001006281) (Filer)
DEF 14A - Protalix BioTherapeutics, Inc. (0001006281) (Filer)
S-3 - Protalix BioTherapeutics, Inc. (0001006281) (Filer)
8-K - Protalix BioTherapeutics, Inc. (0001006281) (Filer)
8-K - Protalix BioTherapeutics, Inc. (0001006281) (Filer)
424B5 - Protalix BioTherapeutics, Inc. (0001006281) (Filer)
10-K - Protalix BioTherapeutics, Inc. (0001006281) (Filer)
8-K - Protalix BioTherapeutics, Inc. (0001006281) (Filer)
8-K - Protalix BioTherapeutics, Inc. (0001006281) (Filer)